Share-based Payment Arrangement, Expense of BIODESIX INC from 30 Sep 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
BIODESIX INC quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2019 to 30 Sep 2025.
  • BIODESIX INC Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,053,000, a 30% decline year-over-year.
  • BIODESIX INC Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $4,329,000, a 33% decline year-over-year.
  • BIODESIX INC annual Share-based Payment Arrangement, Expense for 2024 was $6,638,000, a 24% increase from 2023.
  • BIODESIX INC annual Share-based Payment Arrangement, Expense for 2023 was $5,373,000, a 9.9% decline from 2022.
  • BIODESIX INC annual Share-based Payment Arrangement, Expense for 2022 was $5,961,000, a 21% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

BIODESIX INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $4,329,000 $1,053,000 -$462,000 -30% 01 Jul 2025 30 Sep 2025 10-Q 03 Nov 2025 2025 Q3
Q2 2025 $4,791,000 $1,039,000 -$179,000 -15% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $4,970,000 $972,000 -$1,668,000 -63% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $6,638,000 $1,265,000 +$184,000 +17% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
Q3 2024 $6,454,000 $1,515,000 +$561,000 +59% 01 Jul 2024 30 Sep 2024 10-Q 03 Nov 2025 2025 Q3
Q2 2024 $5,893,000 $1,218,000 +$161,000 +15% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $5,732,000 $2,640,000 +$359,000 +16% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $5,373,000 $1,081,000 -$996,000 -48% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $6,369,000 $954,000 -$216,000 -18% 01 Jul 2023 30 Sep 2023 10-Q 01 Nov 2024 2024 Q3
Q2 2023 $6,585,000 $1,057,000 -$311,000 -23% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $6,896,000 $2,281,000 +$935,000 +69% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $5,961,000 $2,077,000 +$810,000 +64% 01 Oct 2022 31 Dec 2022 10-K 01 Mar 2024 2023 FY
Q3 2022 $5,151,000 $1,170,000 -$216,000 -16% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $5,367,000 $1,368,000 +$829,000 +154% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $4,538,000 $1,346,000 -$406,000 -23% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $4,944,000 $1,267,000 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2023 2022 FY
Q3 2021 $1,386,000 +$1,286,000 +1286% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $539,000 +$484,000 +880% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $1,752,000 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q3 2020 $100,000 +$55,000 +122% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $55,000 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q3 2019 $45,000 01 Jul 2019 30 Sep 2019 10-Q 10 Dec 2020 2020 Q3

BIODESIX INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,638,000 +$1,265,000 +24% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
2023 $5,373,000 -$588,000 -9.9% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
2022 $5,961,000 +$1,017,000 +21% 01 Jan 2022 31 Dec 2022 10-K 01 Mar 2024 2023 FY
2021 $4,944,000 +$1,235,000 +33% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2023 2022 FY
2020 $3,709,000 +$3,539,000 +2082% 01 Jan 2020 31 Dec 2020 10-K 14 Mar 2022 2021 FY
2019 $170,000 01 Jan 2019 31 Dec 2019 10-K 16 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.